LKB1 modulates lung cancer differentiation and metastasis
The DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.
Abstract
Germline mutation in serine/threonine kinase 11 (STK11, also called LKB1) results in Peutz-Jeghers syndrome, characterized by intestinal hamartomas and increased incidence of epithelial cancers. Although uncommon in most sporadic cancers, inactivating somatic mutations of LKB1 have been reported in primary human lung adenocarcinomas and derivative cell lines. Here we used a somatically activatable mutant Kras-driven model of mouse lung cancer to compare the role of Lkb1 to other tumour suppressors in lung cancer. Although Kras mutation cooperated with loss of p53 or Ink4a/Arf (also known as Cdkn2a) in this system, the strongest cooperation was seen with homozygous inactivation of Lkb1. Lkb1-deficient tumours demonstrated shorter latency, an expanded histological spectrum (adeno-, squamous and large-cell carcinoma) and more frequent metastasis compared to tumours lacking p53 or Ink4a/Arf. Pulmonary tumorigenesis was also accelerated by hemizygous inactivation of Lkb1. Consistent with these findings, inactivation of LKB1 was found in 34% and 19% of 144 analysed human lung adenocarcinomas and squamous cell carcinomas, respectively. Expression profiling in human lung cancer cell lines and mouse lung tumours identified a variety of metastasis-promoting genes, such as NEDD9, VEGFC and CD24, as targets of LKB1 repression in lung cancer. These studies establish LKB1 as a critical barrier to pulmonary tumorigenesis, controlling initiation, differentiation and metastasis.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Beyond its role regulating metabolism via AMPK, LKB1 loss promotes tumorigenesis by reprogramming epigenetic states, facilitating lineage plasticity and promoting metastasis22,67–70.”
From LKB1 regulates JNK-dependent stress signaling and apoptotic dependency of KRAS-mutant lung cancers (2025) · cites this paper as [22]
In the citing paper
“Somatic deletion of Lkb1 is insufficient for initiation of lung carcinogenesis in mice as a singular event but dramatically accelerates KrasG12D-driven carcinogenesis and fosters early metastatic dissemination84.”
From Co-occurring genomic alterations in non-small-cell lung cancer biology and therapy (2019) · cites this paper as [84]
In the citing paper
“In addition, loss of Lkb1 results in epigenetic reprogramming and an expanded tumor histological repertoire, with high incidence of squamous or adenosquamous carcinomas, in agreement with data supporting enrichment of LKB1 mutations in human adenosquamous NSCLC84–86.”
From Co-occurring genomic alterations in non-small-cell lung cancer biology and therapy (2019) · cites this paper as [84]
In the citing paper
“Loss of p53 or expression of either dominant negative or dominant gain-of-function Trp53 mutants also co-operate with oncogenic Kras to induce LUADs with shortened latency and increased metastatic proclivity, although these tumors are less aggressive than those with Lkb1 loss69–71, 84.”
From Co-occurring genomic alterations in non-small-cell lung cancer biology and therapy (2019) · cites this paper as [84]
Citations
Cites
Exploration, normalization, and summaries of high density oligonucleotide array probe level data
Irizarry, R. A. (2003) · Biostatistics · doi:10.1093/biostatistics/4.2.249 · Cited by 10,603
Prospective identification of tumorigenic breast cancer cells
Al-Hajj, M., Wicha, M. S., Benito-Hernandez, A., Morrison, S. J., & Clarke, M. F. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0530291100 · Cited by 10,370 · cited 1×
“Only point mutation or deletion 8 of 80 (10) 4 of 42 (10) 1 of 22 (5) 13 of 144 (9) Only single-copy loss by MLPA 11 of 80 (14) 2 of 42 (5) 1 of 22 (5) 14 of 144 (10) Homozygous mutation or deletion 8{ of 80 (10) 2 of 42 (5) 0 of 22 (0) 10 of 144 (7) Total 27 of 80 (34) 8 of 42 (19) 2 of 22 (9) 37 of 144 (26)”
Bolstad, B. M., Irizarry, R. A., Åstrand, M., & Speed, T. P. (2003) · Bioinformatics · doi:10.1093/bioinformatics/19.2.185 · Cited by 8,266
Summaries of Affymetrix GeneChip probe level data
Irizarry, R. A. (2003) · Nucleic Acids Research · doi:10.1093/nar/gng015 · Cited by 4,887 · cited 1×
“Only point mutation or deletion 8 of 80 (10) 4 of 42 (10) 1 of 22 (5) 13 of 144 (9) Only single-copy loss by MLPA 11 of 80 (14) 2 of 42 (5) 1 of 22 (5) 14 of 144 (10) Homozygous mutation or deletion 8{ of 80 (10) 2 of 42 (5) 0 of 22 (0) 10 of 144 (7) Total 27 of 80 (34) 8 of 42 (19) 2 of 22 (9) 37 of 144 (26)”
Identification of Pancreatic Cancer Stem Cells
Li, C., Heidt, D. G., Dalerba, P., Burant, C. F., Zhang, L., Adsay, V., Wicha, M., Clarke, M. F., & Simeone, D. M. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-2030 · Cited by 3,339
Analysis of lung tumor initiation and progression using conditional expression of oncogenic K-ras
Jackson, E. L., Willis, N., Mercer, K., Bronson, R. T., Crowley, D., Montoya, R., Jacks, T., & Tuveson, D. A. (2001) · Genes & Development · doi:10.1101/gad.943001 · Cited by 1,898 · cited 1×
“Only point mutation or deletion 8 of 80 (10) 4 of 42 (10) 1 of 22 (5) 13 of 144 (9) Only single-copy loss by MLPA 11 of 80 (14) 2 of 42 (5) 1 of 22 (5) 14 of 144 (10) Homozygous mutation or deletion 8{ of 80 (10) 2 of 42 (5) 0 of 22 (0) 10 of 144 (7) Total 27 of 80 (34) 8 of 42 (19) 2 of 22 (9) 37 of 144 (26)”
Self-citationRole of the INK4a Locus in Tumor Suppression and Cell Mortality
Serrano, M., Lee, H.-W., Chin, L., Cordon-Cardo, C., Beach, D., & DePinho, R. A. (1996) · Cell · doi:10.1016/s0092-8674(00)81079-x · Cited by 1,585
Molecular Definition of Breast Tumor Heterogeneity
Shipitsin, M., Campbell, L. L., Argani, P., Weremowicz, S., Bloushtain-Qimron, N., Yao, J., Nikolskaya, T., Serebryiskaya, T., Beroukhim, R., Hu, M., et al. (2007) · Cancer Cell · doi:10.1016/j.ccr.2007.01.013 · Cited by 1,353
Somatic activation of the K-ras oncogene causes early onset lung cancer in mice
Johnson, L., Mercer, K., Greenbaum, D., Bronson, R. T., Crowley, D., Tuveson, D. A., & Jacks, T. (2001) · Nature · doi:10.1038/35074129 · Cited by 1,179 · cited 1×
“Only point mutation or deletion 8 of 80 (10) 4 of 42 (10) 1 of 22 (5) 13 of 144 (9) Only single-copy loss by MLPA 11 of 80 (14) 2 of 42 (5) 1 of 22 (5) 14 of 144 (10) Homozygous mutation or deletion 8{ of 80 (10) 2 of 42 (5) 0 of 22 (0) 10 of 144 (7) Total 27 of 80 (34) 8 of 42 (19) 2 of 22 (9) 37 of 144 (26)”
Self-citationThe LKB1 tumor suppressor negatively regulates mTOR signaling
Shaw, R. J., Bardeesy, N., Manning, B. D., Lopez, L., Kosmatka, M., DePinho, R. A., & Cantley, L. C. (2004) · Cancer Cell · doi:10.1016/j.ccr.2004.06.007 · Cited by 1,077
Self-citation
Cited by
Items 201–300 of 1,000
Role of CPS1 in Cell Growth, Metabolism, and Prognosis in LKB1-Inactivated Lung Adenocarcinoma
Çeliktaş, M., Tanaka, I., Tripathi, S. C., Fahrmann, J. F., Aguilar-Bonavides, C., Villalobos, P. A., Delgado, O., Dhillon, D. S., Dennison, J. B., Ostrin, E. J., et al. (2016) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djw231 · Cited by 117
Tam, K. W., Zhang, W., Soh, J., Stastny, V., Chen, M., Sun, H., Thu, K., Rios, J. J., Yang, C., Marconett, C. N., et al. (2013) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e3182a46c0c · Cited by 109
“More recently, STK11 has been identified as being frequently mutated in lung adenocarcinoma and could play an important role in lung cancer differentiation and metastasis.(11,50) However, the relationship between STK11 mutation and p16 inactivation has never been investigated.”
Shan, T., Xiong, Y., Zhang, P., Li, Z., Jiang, Q., Bi, P., Yue, F., Yang, G., Wang, Y., Liu, X., et al. (2016) · Nature Communications · doi:10.1038/ncomms12205 · Cited by 113
Facchinetti, F., Bluthgen, M. V., Tergemina-Clain, G., Faivre, L., Pignon, J., Planchard, D., Remón, J., Soria, J., Lacroix, L., & Besse, B. (2017) · Lung Cancer · doi:10.1016/j.lungcan.2017.08.002 · Cited by 114
The Genomics of Lung Adenocarcinoma: Opportunities for Targeted Therapies
Greulich, H. E. (2010) · Genes & Cancer · doi:10.1177/1947601911407324 · Cited by 119
“STK11 knockout exacerbated KRAS G12D tumorigenesis in a mouse model of lung cancer, and these mice were used to show that a combination of MEK, PI3K, and SRC inhibition caused tumor regression in this model.(126,127) Again, whether this approach has any clinical efficacy remains to be determined.”
MethodBest, S. A., Ding, S., Kersbergen, A., Dong, X., Song, J.-Y., Xie, Y., Reljic, B., Li, K., Vince, J. E., Rathi, V., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-12164-y · Cited by 108
Targeting LKB1 signaling in cancer
Korsse, S. E., Peppelenbosch, M. P., & van Veelen, W. (2012) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2012.12.006 · Cited by 122
“1/7 (14%) [45]”
BackgroundInfluentialSTK11/LKB1 Modulation of the Immune Response in Lung Cancer: From Biology to Therapeutic Impact
Tostivint, E. P., Lugat, A., Fontenau, J.-F., Denis, M. G., & Bennouna, J. (2021) · Cells · doi:10.3390/cells10113129 · Cited by 126
“STK11-deficient tumors had increased expression of genes involved in angiogenesis and cell migration, such as NEDD9 (neural precursor cell expressed developmentally down-regulated 9) [51].”
BackgroundXu, L., Kikuchi, E., Xu, C., Ebi, H., Ercan, D., Cheng, K. A., Padera, R. F., Engelman, J. A., Janne, P. A., Shapiro, G. I., et al. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-3720 · Cited by 117
“As previously described (12, 13, 25, 28-31), transgenic mice were exposed to a doxycycline-containing diet for 8 to 12 weeks, and subjected to magnetic resonance imaging (MRI) to document tumor burden.”
Self-citationMukhopadhyay, S., Huang, H.-Y., Lin, Z., Ranieri, M., Li, S., Sahu, S., Liu, Y., Ban, Y., Guidry, K., Hu, H., et al. (2023) · Cancer Research · doi:10.1158/0008-5472.can-23-2729 · Cited by 105
Self-citationMemmott, R. M., Wolfe, A. R., Carbone, D. P., & Williams, T. M. (2021) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2021.03.017 · Cited by 118
New applications and developments in the use of multiplex ligation‐dependent probe amplification
Kozłowski, P., Jasinska, A. J., & Kwiatkowski, D. J. (2008) · Electrophoresis · doi:10.1002/elps.200800126 · Cited by 103
Self-citationIs AMPK the savior of the failing heart?
Kim, T. T., & Dyck, J. R. B. (2014) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2014.11.001 · Cited by 103
Sox2 Cooperates with Lkb1 Loss in a Mouse Model of Squamous Cell Lung Cancer
Mukhopadhyay, A., Berrett, K. C., Kc, U., Clair, P. M., Pop, S. M., Carr, S. R., Witt, B. L., & Oliver, T. G. (2014) · Cell Reports · doi:10.1016/j.celrep.2014.05.036 · Cited by 103
“LKB1 is lost or mutated in 5%–19% of human SCCs, but loss of Lkb1 alone in the mouse lung does not lead to tumor formation (Ji et al., 2007).”
BackgroundMethodInfluentialLi, N., Wang, Y., Neri, S., Zhen, Y., Fong, L. W. R., Qiao, Y., Li, X., Chen, Z., STEPHAN, C. C., Deng, W., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-12377-1 · Cited by 102
Development of an ObLiGaRe Doxycycline Inducible Cas9 system for pre-clinical cancer drug discovery
Lundin, A., Porritt, M. J., Jaiswal, H., Seeliger, F., Johansson, C., Bidar, A. W., Badertscher, L., Wimberger, S., Davies, E. J., Hardaker, E. L., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-18548-9 · Cited by 104
Kong, C., Wang, C., Wang, L., Ma, M., Niu, C., Sun, X., Du, J., Dong, Z., Zhu, S., Lü, J., et al. (2011) · PLoS ONE · doi:10.1371/journal.pone.0022666 · Cited by 99
“Our data are compatible with the pro-oncogenic role identified for NEDD9 overexpression in glioblastoma, melanoma, and lung cancers [21,22,42].”
ResultZhang, S., Schafer-Hales, K., Khuri, F. R., Zhou, W., Vertino, P. M., & Marcus, A. I. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-2989 · Cited by 93
“This idea is supported by recent work, showing that a somatically activatable mutant Kras-driven model of mouse lung cancer showed that homozygous inactivation of LKB1 resulted in shorter latency and more frequent metastasis compared with tumors lacking p53 or Ink4a/Arf ( 36 ).”
ResultThe stress kinase MKK7 couples oncogenic stress to p53 stability and tumor suppression
Schramek, D., Kotsinas, A., Meixner, A., Wada, T., Elling, U., Pospisilik, J. A., Neely, G. G., Zwick, R. H., Sigl, V., Forni, G., et al. (2011) · Nature Genetics · doi:10.1038/ng.767 · Cited by 115
“These data are in line with previous reports showing that deletion of Tp53 in KRas G12 -driven lung tumor results in increased multiplicity and accelerated malignant progressio”
Cullin5 deficiency promotes small-cell lung cancer metastasis by stabilizing integrin β1
Zhao, G., Gong, L., Su, D., Jin, Y., Guo, C., Yue, M., Yao, S., Qin, Z., Ye, Y., Tang, Y., et al. (2019) · Journal of Clinical Investigation · doi:10.1172/jci122779 · Cited by 96
Self-citationPérez-Johnston, R., Araújo-Filho, J. D. A. B., Connolly, J. G., Caso, R., Whiting, K. A., Tan, K. S., Zhou, J. H., Gibbs, P., Rekhtman, N., Ginsberg, M. S., et al. (2022) · Radiology · doi:10.1148/radiol.211582 · Cited by 108
Spectrum of LKB1, EGFR, and KRAS Mutations in Chinese Lung Adenocarcinomas
Gao, B., Sun, Y., Zhang, J., Ren, Y., Fang, R., Han, X., Shen, L., Liu, X., Pao, W. J., Chen, H., et al. (2010) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e3181e05016 · Cited by 103
Self-citationTargeting LKB1 in Cancer – Exposing and Exploiting Vulnerabilities
Momcilovic, M., & Shackelford, D. B. (2015) · British Journal of Cancer · doi:10.1038/bjc.2015.261 · Cited by 97
LKB1/AMPK/mTOR Signaling Pathway in Non-small-cell Lung Cancer
Han, D., Li, S.-J., Zhu, Y.-T., Liu, L., & Li, M.-X. (2013) · Asian Pacific Journal of Cancer Prevention · doi:10.7314/apjcp.2013.14.7.4033 · Cited by 95
“, 2009) and NSCLC (Shaw and Cantley, 2006; Ji et al., 2007).”
BackgroundZhang, W., Gao, Y., Li, F., Tong, X., Ren, Y., Han, X., Yao, S., Long, F., Yang, Z., Fan, H., et al. (2015) · Cancer Research · doi:10.1158/0008-5472.can-14-3396 · Cited by 92
“Thus, this mouse model represents a clinical-relevant NSCLC subtype, which shows malignant phenotype without effective therapeutic regimens (8).”
BackgroundMethodSelf-citationWalkinshaw, D. R., Weist, R., Kim, G.-W., You, L., Xiao, L., Nie, J., Li, C. S., Zhao, S., Xu, M., & Yang, X.-J. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m113.456996 · Cited by 97
“In addition, LKB1 controls hematopoietic stem cells (38–40) and functions as a tumor suppressor (36, 37).”
BackgroundmRNA Translation and Energy Metabolism in Cancer: The Role of the MAPK and mTORC1 Pathways
Topisirovic, I., & Sonenberg, N. (2011) · Cold Spring Harbor Symposia on Quantitative Biology · doi:10.1101/sqb.2011.76.010785 · Cited by 92
“Somatic LKB1 mutations are frequently detected in non-small-cell lung cancer patients (Sanchez-Cespedes et al. 2002; Ji et al. 2007).”
BackgroundLu, Y., Beezhold, K., Chang, Q., Zhang, Y., Rojanasakul, Y., Zhao, H., Castranova, V., Shi, X., & Chen, F. (2009) · Cell Cycle · doi:10.4161/cc.8.13.8927 · Cited by 103
Wang, G., Cheng, X., Zhou, B., Wen, Z., Huang, Y., Chen, H.-B., Li, G., Huang, Z.-L., Zhou, Y., Feng, L., et al. (2015) · eLife · doi:10.7554/elife.09419 · Cited by 95
“In microarray data sets GSE6135 ( Ji et al., 2007 ), GSE21581 ( Carretero et al., 2010 ), and GSE54353 ( Xu et al., 2014 ) deposited in the Gene Expression Omnibus (GEO; http://www.ncbi.nlm.nih.gov/geo/) from genetically engineered mouse models of lung cancer, Cxcl13 was increased in Kras G12D…”
Winters, I. P., Chiou, S.-H., Paulk, N. K., McFarland, C. D., Lalgudi, P. V., Ma, R. K., Lisowski, L., Connolly, A. J., Petrov, D. A., Kay, M. A., et al. (2017) · Nature Communications · doi:10.1038/s41467-017-01519-y · Cited by 94
The Role of the ECM in Lung Cancer Dormancy and Outgrowth
Parker, A. L., & Cox, T. R. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.01766 · Cited by 103
“In particular, loss of LKB1, which occurs in 34% of adenocarcinoma and 19% of squamous carcinomas (146), induces mTOR-HIF1α signaling to induce lysyl oxidase expression within the tumor microenvironment.”
BackgroundInvolvement of LKB1 in epithelial–mesenchymal transition (EMT) of human lung cancer cells
Roy, B. C., Kohno, T., Iwakawa, R., Moriguchi, T., Kiyono, T., Morishita, K., Sánchez‐Céspedes, M., Akiyama, T., & Yokota, J. (2010) · Lung Cancer · doi:10.1016/j.lungcan.2010.02.004 · Cited by 95
Nedd9/Hef1/Cas-L mediates the effects of environmental pollutants on cell migration and plasticity
Bui, L. C., Tomkiewicz, C., Chevallier, A., Pierre, S., Bats, A., Mota, S. I., Raingeaud, J., Pierre, J., Diry, M., Transy, C., et al. (2009) · Oncogene · doi:10.1038/onc.2009.224 · Cited by 94
“, 2006), which might explain its potential role in cancer progression (Kim et al., 2006; Ji et al., 2007).”
BackgroundInfluentialThe role of the cilium in normal and abnormal cell cycles: emphasis on renal cystic pathologies
Pan, J., Seeger‐Nukpezah, T., & Golemis, E. A. (2012) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-012-1052-z · Cited by 98
Wu, Q., Tian, Y., Zhang, J., Tong, X., Huang, H., Li, S., Zhao, H., Tang, Y., Yuan, C., Wang, K., et al. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1716589115 · Cited by 91
“We have previously shown that somatic loss-of-function mutation of LKB1 is frequently detected in human lung cancer and knockout of Lkb1 significantly promotes tumor progression in the Kras-driven mouse model (10).”
BackgroundSelf-citationp63 and SOX2 Dictate Glucose Reliance and Metabolic Vulnerabilities in Squamous Cell Carcinomas
Hsieh, M.-H., Choe, J. H., Gadhvi, J. G., Kim, Y. J., Arguez, M. A., Palmer, M., Gerold, H., Nowak, C. M., Do, H., Mazambani, S., et al. (2019) · Cell Reports · doi:10.1016/j.celrep.2019.07.027 · Cited by 99
“Glucose Restriction Specifically Suppresses SCC in LSL-KrasG12DLkb1flox/flox LSL-Luc (KLLuc) Genetically Engineered Murine Model (GEMM) We next sought to evaluate the effects of ketogenic diet in the KLLuc mouse model, which develops a full spectrum of NSCLC tumor types including SCC, ADC, and mixed adenosquamous tumo…”
BackgroundRegulation of LKB1/STRAD Localization and Function by E-Cadherin
Sebbagh, M., Santoni, M.-J., Hall, B., Borg, J.-P., & Schwartz, M. A. (2009) · Current Biology · doi:10.1016/j.cub.2008.11.033 · Cited by 82
“Given the known tumor suppressor activity of LKB1 and its role in promoting metastases [1, 26, 27], our results predict that loss of E-cadherin may promote tumorigenesis in part through inhibition of LKB1 function, which would lead to increased mTOR activity as well as contributing to the loss of polarity.”
Régina, S., Valentin, J.-B., Lachot, S., Lemarié, É., Rollin, J., & Gruel, Y. (2009) · Clinical Chemistry · doi:10.1373/clinchem.2009.123695 · Cited by 100
“309 550 All 1 4 74 485 TP53 + PTEN + KRAS (2) 106 405 TP53 + PTEN + STK11 (2) 97 530 PTEN + STK11 + KRAS (1) 16 500 TP53 + PTEN (7) 19 150 STK11 + KRAS (5) 6305 TP53 + STK11(4) 17 370 STK11 + PTEN (2) 18 2 11 045 STK11 (8) 13 710 PTEN (5) 2030 TP53 (3) 16 1 1500 12 0 Median number of TF mRNA copies Mutated genes”
Novel Insight into Mutational Landscape of Head and Neck Squamous Cell Carcinoma
Gaykalova, D. A., Mambo, E., Choudhary, A. K., Houghton, J., Buddavarapu, K., Sanford, T., Darden, W., Adai, A. T., Hadd, A. G., Latham, G. J., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0093102 · Cited by 99
“49 STK11 NSCLC; pancreatic yes Signal transduction pathways [88,89] whole exon HNSCC Mutational Landscape”
BackgroundThe interplay between autophagy and apoptosis: its implication in lung cancer and therapeutics
Biswas, U., Roy, R., Ghosh, S., & Chakrabarti, G. (2024) · Cancer Letters · doi:10.1016/j.canlet.2024.216662 · Cited by 96
HEF1, a novel target of Wnt signaling, promotes colonic cell migration and cancer progression
Li, Y., Bavarva, J. H., Wang, Z., Guo, J., Qian, C., Thibodeau, S. N., Golemis, E. A., & Liu, W. (2011) · Oncogene · doi:10.1038/onc.2010.632 · Cited by 97
“High levels of HEF1 have been reported in various human cancers including melanoma and lung cancer, while deletion of HEF1 limited the growth of mammary tumors in MMTVpolyoma virus T antigen mice (Kim et al., 2006; Ji et al., 2007; Izumchenko et al., 2009).”
InfluentialLKB1 loss promotes endometrial cancer progression via CCL2-dependent macrophage recruitment
Peña, C. G., Nakada, Y., Saatcioglu, H. D., Aloisio, G. M., Cuevas, I., Zhang, S., Miller, D. S., Lea, J. S., Wong, K., DeBerardinis, R. J., et al. (2015) · Journal of Clinical Investigation · doi:10.1172/jci82152 · Cited by 96
“1172/ JCI82152DS1), consistent with the idea that additional genetic changes are needed to transform EM cells and in agreement with studies showing that LKB1 has a relatively modest impact on cell proliferation and instead acts as a tumor suppressor principally through its control of other biological processes (6, 35).”
BackgroundSelf-citationTang, K.-J., Constanzo, J. D., Venkateswaran, N., Melegari, M., Ilcheva, M., Morales, J. C., Skoulidis, F., Heymach, J. V., Boothman, D. A., & Scaglioni, P. P. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-2603 · Cited by 91
LKB1 deficiency-induced metabolic reprogramming in tumorigenesis and non-neoplastic diseases
Zhang, Y., Meng, Q., Sun, Q., Xu, Z., Zhou, H., & Wang, Y. (2020) · Molecular Metabolism · doi:10.1016/j.molmet.2020.101131 · Cited by 97
“Nevertheless, the loss of LKB1 leads to metabolic friability, and LKB1 deficiency may co-occur with other deficiencies, such as Kras activation in NSCLC cells [11], HPV infection in cervical cancer cells [8], B-RAF in melanoma [63], or TSC1 mutants in kidneys [19], which may accelerate disease progression.”
BackgroundDifferent prognostic impact of STK11 mutations in non-squamous non-small-cell lung cancer
Pécuchet, N., Laurent-Puig, P., Mansuet-Lupo, A., Legras, A., Alifano, M., Pallier, K., Didelot, A., Gibault, L., Danel, C., Just, P.-A., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.6379 · Cited by 87
“Although STK11 is inactivated by a large spectrum of truncating mutation and behave as a tumor suppressor gene in different tumor models through mTOR inhibition [9-11], recent studies suggest that STK11 may also gain oncogenic properties.”
Niwa, O., Barcellos‐Hoff, M. H., Globus, R. K., Harrison, J. D., Hendry, J. H., Jacob, P., Martin, M. T., Seed, T. M., Shay, J. W., Story, M. D., et al. (2015) · Annals of the ICRP · doi:10.1177/0146645315595585 · Cited by 102
“These inactivating mutations are associated with the loss of barriers to initiation, and altered cell polarity and metastasis (Ji et al., 2007).”
BackgroundGenome-wide identification of transcription factors that are critical to non-small cell lung cancer
Zhang, D.-L., Qu, L.-W., Ma, L., Zhou, Y., Wang, G., Zhao, X., Zhang, C., Zhang, Y., Wang, M., Zhang, M., et al. (2018) · Cancer Letters · doi:10.1016/j.canlet.2018.07.020 · Cited by 97
“These genes included AF4/FMR2 family member 3 (AFF3, or LAF4) [35] (Figure 2A), aryl hydrocarbon receptor (AHR) [36] (Figure 2B), androgen receptor (AR) [37] (Figure 2C), CBFA2T3 [38] (Figure 2D), chromodomain helicase DNA binding protein 4 (CHD4) [39] (Figure 2E), KN motif and ankyrin repeat domains 2 (KANK2) [40] (F…”
AMPK Causes Cell Cycle Arrest in LKB1-Deficient Cells via Activation of CAMKK2
Fogarty, S., Ross, F. A., Vara‐Ciruelos, D., Gray, A., Gowans, G. J., & Hardie, D. G. (2016) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-15-0479 · Cited by 99
“We therefore expressed in G361 cells either full-length human CAMKK2 (1-588) or a truncated form (1–471; residue 471 aligns with residue 434 in rat CAMKK1).”
BackgroundLung Stem and Progenitor Cells in Tissue Homeostasis and Disease
Leeman, K. T., Brainson, C. F., & Kim, C. F. (2014) · Current topics in developmental biology/Current Topics in Developmental Biology · doi:10.1016/b978-0-12-416022-4.00008-1 · Cited by 99
Wu, D., Zhuo, L., & Wang, X. (2016) · Seminars in Cell and Developmental Biology · doi:10.1016/j.semcdb.2016.11.003 · Cited by 93
Single-sample landscape entropy reveals the imminent phase transition during disease progression
Liu, R., Chen, P., & Chen, L. (2019) · Bioinformatics · doi:10.1093/bioinformatics/btz758 · Cited by 90
Self-citationOncogene-Driven Metabolic Alterations in Cancer
Min, H., & Lee, H. (2017) · Biomolecules & Therapeutics · doi:10.4062/biomolther.2017.211 · Cited by 92
“Approximately 15-35% of NSCLC patients harbor mutations in STK11 (Ji et al., 2007; Shackelford and Shaw, 2009), which is more frequently observed in lung ADC than in lung SQCC (Sanchez-Cespedes et al., 2002; Ji et al., 2007).”
BackgroundKaufman, J. M., Amann, J. M., Park, K., Arasada, R. R., Li, H., Shyr, Y., & Carbone, D. P. (2014) · Journal of Thoracic Oncology · doi:10.1097/jto.0000000000000173 · Cited by 87
“One such tumor suppressor is LKB1, a serine-threonine kinase tumor suppressor that is lost in approximately 30% of lung adenocarcinomas.(1,2) It is a key regulator of cellular metabolism through its control of the adenosine monophosphate–activated protein kinase (AMPK); loss of this metabolic checkpoint in tumors resu…”
BackgroundLKB1 Is Necessary for Akt-Mediated Phosphorylation of Proapoptotic Proteins
Zhong, D., Liu, X., Khuri, F. R., Sun, S., Vertino, P. M., & Zhou, W. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-1484 · Cited by 87
“64 ELRRMpSDEFV PKA Cell survival/apoptosis (6, 7)”
Baba, Y., Nosho, K., Shima, K., Meyerhardt, J. A., Chan, A. T., Engelman, J. A., Cantley, L. C., Loda, M. F., Giovannucci, E. L., Fuchs, C. S., et al. (2010) · British Journal of Cancer · doi:10.1038/sj.bjc.6605846 · Cited by 86
Zhao, N., Wilkerson, M. D., Shah, U., Yin, X., Wang, A., Hayward, M. C., Roberts, P., Lee, C. B., Parsons, A. M., Thorne, L. B., et al. (2014) · Lung Cancer · doi:10.1016/j.lungcan.2014.08.013 · Cited by 84
“In this study, we seek to identify how LKB1 alteration, assessed by gene mutation, gene expression (GE) and copy number (CN) change, can predict brain metastasis in a group of NSCLC patients in conjunction with KRAS aberration, which has been shown to have a synergistic effect with LKB1 inactivation in lung cancer dev…”
BackgroundInfluentialSelf-citationClinical and Molecular Characteristics of NF1 -Mutant Lung Cancer
Redig, A. J., Capelletti, M., Dahlberg, S. E., Sholl, L. M., Mach, S., Fontes, C., Shi, Y., Chalasani, P., & Jänne, P. A. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-2377 · Cited by 84
“Multiple lines of evidence indicate that variables as divergent as specific exon/base-pair KRAS mutation (47) or coexisting mutations in key tumor-suppressor genes (21, 48, 49) may help shape the biologic heterogeneity of tumors with a KRAS mutation.”
BackgroundDai, J., Wie, P. V., Yenwongfai, L. N., Kim, D., Wang, L., Pratheeshkumar, P., Luo, J., & Zhang, Z. (2016) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2016.09.016 · Cited by 84
Inflammation as a driver and vulnerability of KRAS mediated oncogenesis
Kitajima, S., Thummalapalli, R., & Barbie, D. A. (2016) · Seminars in Cell & Developmental Biology · doi:10.1016/j.semcdb.2016.06.009 · Cited by 84
“However, a more defined role for IL6 in promoting lung cancer pathogenesis was recently demonstrated in the LSL-KrasG12D;Lkb1Flox/Flox (KL) model [14], an equally if not more aggressive model compared to KP mice [15].”
ResultDysregulation of Glucose Metabolism by Oncogenes and Tumor Suppressors in Cancer Cells
Marbaniang, C., & Kma, L. (2018) · PubMed · doi:10.22034/apjcp.2018.19.9.2377 · Cited by 79
“LKb1 is also frequently mutated in sporadic cases of non-small-cell lung cancer (Ji, 2007) and cervical carcinoma (Wingo, 2009).”
BackgroundLkb1 Deficiency Causes Prostate Neoplasia in the Mouse
Pearson, H. B., McCarthy, A., Collins, C. M. P., Ashworth, A., & Clarke, A. R. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-5169 · Cited by 76
“However, the fact that somatic LKB1 mutations have been observed in human lung cancer and the observation of Lkb1-driven lung tumorigenesis in the mouse suggests that Lkb1 may have a broad tumor suppressive role in epithelial tissues ( 12 ).”
BackgroundInfluentialLKB1 Deficiency Sensitizes Mice to Carcinogen-Induced Tumorigenesis
Gurumurthy, S., Hezel, A. F., Berger, J. H., Bosenberg, M. W., & Bardeesy, N. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-3225 · Cited by 82
Self-citationHIF, hypoxia and the role of angiogenesis in non-small cell lung cancer
Jackson, A. L., Zhou, B., & Kim, W. Y. (2010) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2010.511617 · Cited by 78
“While homozygous deletion of the tuberous sclerosis complex (either TSC1 or TSC2) appears to be a relatively rare event in NSCLC, somatic mutations of the PTEN and LKB1 tumor suppressor genes have been found in up to 6 and 30% of NSCLC patients respectively [73-75].”
Gu, Y., Lin, S., Li, J., Nakagawa, H., Chen, Z., Jin, B., Tian, L., Uçar, D. A., Shen, H., Lu, J., et al. (2011) · Oncogene · doi:10.1038/onc.2011.247 · Cited by 81
“LKB1 loss promotes esophageal cancer cell migration and invasion Studies with a mouse model of non-small cell lung cancer showed that LKB1 inactivation enhanced K-RAS-mediated metastasis and affected tumor initiation and differentiation, revealing a role for LKB1 in cancer metastasis (Ji et al., 2007; Carretero et al.…”
BackgroundResultThe LKB1-AMPK Pathway—Friend or Foe in Cancer?
Hardie, D. G. (2013) · Cancer Cell · doi:10.1016/j.ccr.2013.01.009 · Cited by 81
Chapter 2 Cell Signaling in Protein Synthesis
Mahoney, S. J., Dempsey, J. M., & Blenis, J. (2009) · Progress in molecular biology and translational science · doi:10.1016/s1877-1173(09)90002-3 · Cited by 92
The MZF1/c-MYC axis mediates lung adenocarcinoma progression caused by wild-type lkb1 loss
Tsai, L.-H., Wu, J.-Y., Cheng, Y.-W., Chen, C.-Y., Sheu, G., Wu, T.-C., & Lee, H. (2014) · Oncogene · doi:10.1038/onc.2014.118 · Cited by 80
The serine-threonine kinase LKB1 is essential for survival under energetic stress in zebrafish
van der Velden, Y. U., Wang, L., Zevenhoven, J., van Rooijen, E., van Lohuizen, M., Giles, R. H., Clevers, H. C., & Haramis, A.-P. G. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1010210108 · Cited by 79
“Furthermore, somatic mutations in LKB1 have been recently identified in ∼30% of lung adenocarcinomas (4) and have been identified as a somatic recurrent mutation in endometrial cancer (5).”
BackgroundMak, R. H., Hermann, G., Lewis, J. H., Aerts, H. J. W. L., Baldini, E. H., Chen, A. B., Colson, Y. L., Hacker, F., Kozono, D., Wee, J. O., et al. (2014) · Clinical Lung Cancer · doi:10.1016/j.cllc.2014.09.005 · Cited by 79
“Similarly, this 22 study was conducted in an era where clinical genotyping involved only a limited panel of 23 genes (KRAS, EGFR, and ALK), and thus, co-mutations in genes that are known to alter 24 the underlying biology of KRAS mutant tumors such as LKB1 and p53 were not 25 genotyped.(22) Clearly, further studies an…”
Self-citationRegulation of invasive behavior by vascular endothelial growth factor is HEF1-dependent
Lucas, J. T., Salimath, B. P., Slomiany, M. G., & Rosenzweig, S. A. (2010) · Oncogene · doi:10.1038/onc.2010.185 · Cited by 88
“Additional support for HEF1 in cell migration/ invasion comes from studies of multiple cancer cell types (Singh et al., 2008), metastatic melanoma (Kim et al., 2006), breast cancer (Izumchenko et al., 2009), lung cancer (Ji et al., 2007) and head and neck cancer (Yu et al., 2008).”
BackgroundInfluentialPrakasam, G., Singh, R. K., Iqbal, M. A., Saini, S. K., Tiku, A. B., & Bamezai, R. N. K. (2017) · Journal of Biological Chemistry · doi:10.1074/jbc.m117.791343 · Cited by 83
Molecular mechanisms of tumor suppression by LKB1
Vaahtomeri, K., & Mäkelä, T. P. (2010) · FEBS Letters · doi:10.1016/j.febslet.2010.12.034 · Cited by 87
“In a mouse lung cancer model driven by KRAS mutations inactivation of Lkb1 increased tumorigenicity more than p53 mutations consistent with the notion that LKB1 and KRAS cooperate in lung tumorigenesis [13].”
BackgroundInfluentialTikhmyanova, N., & Golemis, E. A. (2011) · PLoS ONE · doi:10.1371/journal.pone.0022102 · Cited by 83
“NEDD9 overexpression is frequent in glioblastomas [13], melanomas [14], and some lung cancers [15], and promotes metastasis; upregulation of NEDD9 also promotes oncogenic signaling in the hematopoietic system [16,17,18,19,20], and supports invasive behavior in breast cancer cell lines [21], while genetic ablation of N…”
BackgroundRicciardelli, C., Lokman, N. A., Cheruvu, S., Tan, I. A., Ween, M. P., Pyragius, C. E., Ruszkiewicz, A. R., Hoffmann, P., & Oehler, M. K. (2015) · Clinical & Experimental Metastasis · doi:10.1007/s10585-015-9718-1 · Cited by 85
“The TKT activator benfotiamine stimulates the activity of PPP enzymes and the phosphorylation/activation of VEGFR2 in a diabetic animal model [74].”
Karachaliou, N., Rosell, R., & Viteri, S. (2013) · Europe PMC (PubMed Central) · doi:10.3978/j.issn.2218-6751.2013.01.01 · Cited by 78
“Inducible deletion of the tumor suppressor liver kinase B1 (LKB1) along with inducible expression of oncogenic K-Ras leads to adenocarcinoma with squamous features as well (34).”
BackgroundTranscriptional suppression of AMPKα1 promotes breast cancer metastasis upon oncogene activation
Yi, Y., Chen, D., Ao, J., Zhang, W., Yi, J., Ren, X., Fei, J., Li, F., Niu, M., Chen, H., et al. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1914786117 · Cited by 81
“In addition, knockout of LKB1 promotes K-Ras-driven lung cancer metastasis in mice (10, 13).”
BackgroundPhase separation of EML4–ALK in firing downstream signaling and promoting lung tumorigenesis
Qin, Z., Sun, H., Yue, M., Pan, X., Chen, L., Feng, X., Yan, X., Zhu, X., & Ji, H. (2021) · Cell Discovery · doi:10.1038/s41421-021-00270-5 · Cited by 80
Self-citationGenetic and epigenetic changes in lung carcinoma and their clinical implications
Wen, J., Fu, J., Zhang, W., & Guo, M. (2011) · Modern Pathology · doi:10.1038/modpathol.2011.46 · Cited by 87
AMP-activated protein kinase: Structure, function, and role in pathological processes
Novikova, D., Garabadzhiu, A. V., Melino, G., Barlev, N. A., & Tribulovich, V. G. (2015) · Biochemistry (Moscow) · doi:10.1134/s0006297915020017 · Cited by 86
“Mutations in LKB1 lead to development of Peutz–Jeghers syndrome (PJS), which is associated with the loss of kinase activity as well as some cancers [51, 52].”
BackgroundLKB1 Regulated Pathways in Lung Cancer Invasion and Metastasis
Marcus, A. I., & Zhou, W. (2010) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e3181fbc28a · Cited by 80
“In a seminal publication, LKB1 function was assessed using a mutant k-ras driven mouse model of lung cancer 16 .”
MethodThe tumor suppressor kinase LKB1: lessons from mouse models
Ollila, S., & Mäkelä, T. P. (2011) · Journal of Molecular Cell Biology · doi:10.1093/jmcb/mjr016 · Cited by 87
“Importantly, somatic LKB1 mutations are found at least in lung (Ji et al., 2007) and cervical cancer (Wingo et al., 2009).”
BackgroundInfluentialHou, S., Zhou, S., Qin, Z., Liu, Y., Han, X., Yao, S., & Ji, H. (2017) · American Journal Of Pathology · doi:10.1016/j.ajpath.2017.01.009 · Cited by 83
“These cell autonomous and nonecell autonomous signals triggered by Lkb1 loss might work synergistically to promote lung cancer metastasis.(30,32) How the SCCs develop in KL Ad-Cre mouse model remains as an intriguing question.”
BackgroundInfluentialSelf-citationMetabolic rewiring in mutant Kras lung cancer
Kerr, E. M., & Martins, C. P. (2017) · FEBS Journal · doi:10.1111/febs.14125 · Cited by 84
Overcoming Resistance to Dual Innate Immune and MEK Inhibition Downstream of KRAS
Kitajima, S., Asahina, H., Chen, T., Guo, S., Quiceno, L. G., Cavanaugh, J. D., Merlino, A. A., Tange, S., Terai, H., Kim, J. W., et al. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.08.009 · Cited by 75
Self-citationMetformin impairs the growth of liver kinase B1-intact cervical cancer cells
Xiao, X., He, Q., Lu, C., Werle, K. D., Zhao, R.-X., Chen, J., Davis, B. C., Cui, R., Liang, J., & Xu, Z.-X. (2012) · Gynecologic Oncology · doi:10.1016/j.ygyno.2012.06.032 · Cited by 80
“Inactivating mutations in LKB1 are also found in cancer patients without PJS, such as those with sporadic lung adenocarcinoma, ovarian and breast cancer, and pancreatic cancer [8–11].”
BackgroundOllila, S., Domènech‐Moreno, E., Laajanen, K., Wong, I. P. L., Tripathi, S., Pentinmikko, N., Gao, Y., Yan, Y., Niemelä, E. H., Wang, T. C., et al. (2017) · Journal of Clinical Investigation · doi:10.1172/jci93597 · Cited by 77
Hata, A. N., Yeo, A., Faber, A. C., Lifshits, E., Chen, Z., Cheng, K. A., Walton, Z., Sarosiek, K. A., Letai, A., Heist, R. S., et al. (2014) · Cancer Research · doi:10.1158/0008-5472.can-13-3728 · Cited by 74
“We also examined the response ofKras-mutant tumors with secondary Trp53 deletion (22) to treatment with AZD6244/BEZ235 and observed a transient response of intermediate magnitude (60% reduction in tumor volume) that was followed by rapid development of drug resistance after 4 weeks (Supplementary Fig.”
Self-citationBange, E., Marmarelis, M. E., Hwang, W.-T., Yang, Y.-X., Thompson, J. C., Rosenbaum, J., Bauml, J. M., Ciunci, C., Alley, E. W., Cohen, R. B., et al. (2019) · JCO Precision Oncology · doi:10.1200/po.18.00326 · Cited by 74
“Animal studies suggest that STK11 mutations are critical in lung cancer differentiation, tumorigenesis, and metastasis.(4,5) Mutations in STK11 have emerged as a potential prognostic and predictive marker in NSCLC.”
BackgroundDishevelled has a YAP nuclear export function in a tumor suppressor context-dependent manner
Lee, Y., Kim, N. H., Cho, E. S., Yang, J. H., Cha, Y. H., Kang, H. E., Yun, J. S., Cho, S. B., Lee, S.-H., Paclíková, P., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-04757-w · Cited by 77
Han, Y., Feng, H., Sun, J., Liang, X., Wang, Z., Xing, W., Dai, Q., Yang, Y., Han, A., Wei, Z., et al. (2019) · Journal of Clinical Investigation · doi:10.1172/jci124590 · Cited by 74
“Lkb1fl/fl mice were obtained as previously described (18, 57).”
Self-citationRetractedLkb1 Is Indispensable for Skeletal Muscle Development, Regeneration, and Satellite Cell Homeostasis
Shan, T., Zhang, P., Liang, X., Bi, P., Yue, F., & Kuang, S. (2014) · Stem Cells · doi:10.1002/stem.1788 · Cited by 69
Song, P., Xie, Z., Wu, Y., Xu, J., Dong, Y., & Zou, M.-H. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m708208200 · Cited by 70
RetractedYao, Y., Cui, Y., Qiu, X., Zhang, L., Zhang, W., Li, H., & Yu, J. (2016) · 癌症:英文版 · doi:10.1186/s40880-016-0113-3 · Cited by 72
“Using the mouse model of oncogenic Kras-driven lung cancer, LKB1 has been shown to be a critical barrier to lung cancer initiation and metastasis [14].”
Tan, X., Lu, T., Li, L., Xu, J., Xie, S., Ji, L., Fu, J., Liu, Q., Shen, S., Liu, Y., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-24898-9 · Cited by 72
Self-citationHan, J. H., Kim, Y. K., Kim, H., Lee, J., Oh, M. J., Kim, S. B., Kim, M., Kim, K. H., Yoon, H. J., Lee, M., et al. (2022) · 癌症:英文版 · doi:10.1002/cac2.12332 · Cited by 79
“Specifically, patients harboring mutations in KRAS and the tumor suppressor gene LKB1, two commonly mutated genes in NSCLC, develop aggressive lung tumors, show a high frequency of metastasis and are refractory to the currently available therapies [7, 8].”
BackgroundLKB1 inhibits HPV-associated cancer progression by targeting cellular metabolism
Zeng, Q., Chen, J., Li, Y., Werle, K. D., Zhao, R.-X., Quan, C.-S., Wang, Y.-S., Zhai, Y.-X., Jw, W., Youssef, M., et al. (2016) · Oncogene · doi:10.1038/onc.2016.290 · Cited by 74
LOXL1 Is Regulated by Integrin α11 and Promotes Non-Small Cell Lung Cancer Tumorigenicity
Zeltz, C., Pasko, E., Cox, T. R., Navab, R., & Tsao, M. (2019) · Cancers · doi:10.3390/cancers11050705 · Cited by 75
“Lkb1-deficient mice display enhanced metastasis and Loxl1 is among a set of genes that are up-regulated in these mice [17].”
BackgroundDhanasekaran, R., Baylot, V., Kim, M., Kuruvilla, S. P., Bellovin, D. I., Adeniji, N., Rajan, A., Lai, I. K., Gabay, M., Tong, L., et al. (2020) · eLife · doi:10.7554/elife.50731 · Cited by 75
“Many studies have examined human clinical specimens and/or tumor-derived cell lines to discern mechanisms of metastasis, and identified the role of specific genes (Ji et al., 2007; Sun et al., 2018; Zhu et al., 2017) and also the role of the tumor microenvironment (Fidler, 2003; Kalluri, 2016; Kim et al.”
BackgroundThe dark face of AMPK as an essential tumor promoter
Jeon, S., & Hay, N. (2012) · Cellular Logistics · doi:10.4161/cl.22651 · Cited by 75
Lineage factors and differentiation states in lung cancer progression
Cheung, W. K. C., & Nguyen, D. X. (2015) · Oncogene · doi:10.1038/onc.2015.85 · Cited by 80
Metadata
- Authors
- Ji, H., Ramsey, M. R., Hayes, D. N., Fan, C., McNamara, K., Kozlowski, P., Torrice, C., Wu, M. C., Shimamura, T., Perera, S. A., Liang, M.-C., Cai, D., Naumov, G. N., Bao, L., Contreras, C. M., Li, D., Chen, L., Krishnamurthy, J., Koivunen, J., Chirieac, L. R., Padera, R. F., Bronson, R. T., Lindeman, N. I., Christiani, D. C., Lin, X., Shapiro, G. I., Jänne, P. A., Johnson, B. E., Meyerson, M., Kwiatkowski, D. J., Castrillon, D. H., Bardeesy, N., Sharpless, N. E., & Wong, K.-K.
- Affiliations
- Dana-Farber Cancer Institute (US)
- University of North Carolina at Chapel Hill (US)
- Harvard University (US)
- University of Tennessee Health Science Center (US)
- Harold C. Simmons Comprehensive Cancer Center (US)
- Brigham and Women's Hospital (US)
- Broad Institute (US)
- Massachusetts General Hospital (US)
- Corresponding author
- Bardeesy, Nabeel
- Sharpless, Norman E.
- Wong, Kwok-Kin
- ORCID
- Ji, Hongbin
- Ramsey, Matthew R.
- Hayes, D. Neil
- Wu, Michael C.
- Shimamura, Takeshi
- Perera, Samanthi A.
- Liang, Mei-Chih
- Bao, Lei
- Chen, Liang
- Koivunen, Jussi
- Chirieac, Lucian R.
- Padera, Robert F.
- Bronson, Roderick T.
- Lindeman, Neal I.
- Christiani, David C.
- Lin, Xihong
- Shapiro, Geoffrey I.
- Johnson, Bruce E.
- Meyerson, Matthew
- Kwiatkowski, David J.
- Bardeesy, Nabeel
- Sharpless, Norman E.
- Wong, Kwok-Kin
- Venue
- Nature
- Published
- 2007-08-05
- Volume
- 448
- Issue
- 7155
- Pages
- 807-810
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W2134964552
- Cited by
- 1,064
- References
- 36
- Citations by year
- 2026: 30 · 2025: 43 · 2024: 44 · 2023: 66 · 2022: 50 · 2021: 71 · 2020: 51 · 2019: 66 · 2018: 61 · 2017: 56 · 2016: 54 · 2015: 72 · 2014: 83 · 2013: 65 · 2012: 52
- FWCI
- 24.29
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- The Mouseion at the JAXlibrary (Jackson Laboratory) (submittedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Lung Cancer Research Studies
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Keywords
- LKB1, STK11, lung cancer, tumour suppressor, metastasis, squamous cell carcinoma, non-small cell lung cancer, KRAS, p53, Ink4a/Arf, CDKN2A, tumor differentiation, Peutz-Jeghers syndrome, metastasis-promoting genes
- MeSH terms
- AMP-Activated Protein Kinase Kinases, Animals, Carcinoma, Non-Small-Cell Lung, Cell Differentiation, Disease Models, Animal, Humans, Lung Neoplasms, Neoplasm Metastasis, Genes, ras, Gene Expression Regulation, Neoplastic, Genes, Tumor Suppressor, Genes, p53, Protein Serine-Threonine Kinases, Genes, p16, Gene Expression Profiling, Cell Line, Tumor, Mice, Genes, Neoplasm, AMP-Activated Protein Kinases
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.